Dr. Regina Hodits is the Spokesperson of the Board of the German Private Equity and Venture Capital Association (BVK). She is the mission leader of the BVK to London, UK.
Regina is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Endostim, GTX, Themis, Rigontec, Middle Peak Medical and Ayoxxa. She was a founding investor in Sapiens, which was sold to Medtronic. For Apax and Atlas, Regina managed investment in Genmab, Horizon Pharma, Novamed/Sciclone, F-star and Bicycle, and she was an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, Regina has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry. Regina became Spokesperson of the Board of the BVK in June 2017, and has been a Board member since June 2016.
Wellington Partners Life Sciences (WPLS) is a leading European venture capital firm investing in early- and growth-stage Life Science companies, active in the fields of Therapeutics, Medical Technology, Diagnostics, Digital Health and Industrial Biotechnology. With funds totaling more than €200 million, we have been actively supporting world-class private companies translating true innovation into successful businesses of exceptional growth. From 2007 onwards, we have been investing with dedicated Life Science funds becoming a premier European provider of venture capital for the financing of breakthrough products with the potential to decisively improve current standard of care and most importantly, the lives of patients. WPLS has invested in more than 25 Life Science companies, including publicly listed firms like Actelion (subsequently acquired by J&J) and Oxford Immunotec, as well as privately held companies like Definiens (acquired by AZ/Medimmune), MTM Laboratories (acquired by Roche), Rigontec, Sapiens (acquired by Medtronic), and Symetis (acquired by Boston Scientific).
For further information, please visit www.wellington-partners.com/ls
The German Private Equity and Venture Capital Association (BVK) is the Berlin-based association of private equity and venture capital firms across all market segments (seed capital, venture capital, growth capital, small/mid/large buy-outs) operating in Germany. BVK has more than 185 full and 100 associate members. Also Limited Partners are full members of the association. BVK is the only voice of private equity and venture capital in Germany and aims at creating the best possible conditions for the asset class in Germany.
Please visit www.bvkap.de for more information.
Michael Stuenkel joined Lakestar in October 2009 and was part of the founding team. He has led investments in technology companies both in emerging and established markets. Beside his investment activities, Michael led the fundraising processes for several Lakestar funds and raised in total approx. €500 million of third-party capital. Prior to joining Lakestar, Michael worked for UBS in London where he worked on several high-profile IPOs, capital raisings and M&A transactions. Michael completed his undergraduate studies in Business Administration at WHU and HKUST and holds a Master of Finance from the LSE.
Lakestar is a Europe-centric global VC with offices in Berlin, London and Zurich. We conduct early and growth stage investments in disruptive, technology-enabled businesses. Our seasoned team has a proven track record of building transatlantic bridges and successfully scaling companies in Europe and the United States. Past investments include Facebook, Spotify, Skype, AirBnB, Klarna, and King.com, and more recently Algomi, Blockchain, GoEuro, Oscar, Opendoor, Maker Studios, and Harry’s.
Christian Schuetz, a General Partner at btov, is responsible for the industrial technology investments. He joined the firm in 2003 as Investment Manager and became a Partner in 2008. Since 2003, he has been managing over 20 investments in start-up companies and the set-up and reporting of the btov funds in Luxembourg. He is member of the btov Board of Directors and General Partner of btov’s Funds. Christian studied international business administration, holds a master’s degree and earned a PhD in Banking and Entrepreneurial Finance from the European Business School (ebs), Oestrich-Winkel.
btov Partners is a European venture capital company with offices in Berlin, Luxembourg and St. Gallen, focusing on digital and industrial technology companies. btov manages its own funds, partner funds and offers private individuals and family offices access to direct investments. Across its three divisions, the company manages assets worth more than €330 million and examines more than 3‘000 investment opportunities annually. Examples of portfolio companies are Data Artisans, Blacklane, SumUp, Raisin, Effect Photonics or Orcam.
Further information is available at www.btov.vc
Sascha Alilovic is a Venture Partner of SHS since 2017. He is Head of Corporate Finance & Corporate Development with the MorphoSys AG, responsible for all M&A, capital markets and corporate venture capital topics in Germany’s foremost biotech company. Moreover, Mr. Alilovic has been in charge of numerous acquisitions and sales of companies, investment projects as well as financing and licensing topics at MorphoSys. During his previous positions with Siemens and corporate finance boutiques he handled complex corporate transactions, IPOs, financing operations and outsourcing deals with an overall volume exceeding €10 billion. Mr. Alilovic studied business administration at the European Business School and information technology at the James Madison University. He is a member of the Life Science Commission of the German Financial Analysts Association (DVFA) and a speaker at Life Science conferences.
SHS Gesellschaft für Beteiligungsmanagement (SHS) was founded in 1993 and is based in Tübingen, Germany. SHS primarily invests in medical technology and diagnostics companies in the German speaking regions, with a focus on growth financing and small buy-outs. The AIFM-registered company is currently investing from its fourth generation of funds, for which investors have provided more than €125 million. Reinhilde Spatscheck, Dr. Bernhard Schirmers, Hubertus Leonhardt and Uwe Steinbacher are the Managing Partners of SHS.
For further information, please visit www.shs-capital.eu
Stefan Fischer joined TVM Capital in 2000 and is General Partner and CFO at TVM Capital based in Munich. He has been responsible for the corporate finance side of the investment activities of the life science team for many years and was actively involved in numerous IPOs and trade sales of TVM Capital portfolio companies. Since 2012, he also assumes the role of being the Chief Financial Officer of the firm. Mr. Fischer represents TVM on several portfolio boards and holds overall responsibility for the finance operations of the firm’s offices in Munich, Montreal and Hong Kong as well as for TVM’s life science venture capital funds. Prior to joining TVM Capital, Mr. Fischer spent few years as a consultant in the corporate finance department of KPMG. Mr. Fischer earned a master degree in business administration at the University of Passau.
TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-years of transatlantic investment track record and more than US$1.4 billion raised and under management. With its advisory, corporate finance and investment teams located in Montreal, Munich and Hong Kong, the TVM Capital Life Science team provides investors as well as entrepreneurs and innovation-seeking biopharmaceutical companies’ access to global life science innovation and provides paths for successful tech transfer and commercialization for the benefit of patients and investors alike. The TVM Capital Life Science international team looks back on more than 133 investments and over 90 exits, including more than 50 initial public offerings on all major U.S. and European stock exchanges and has gained unrivalled international investment experience with their track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets.
More information: www.tvm-lifescience.com
Dr. Fabian Heilemann is a digital serial-entrepreneur and managing partner in the western European early stage fund of Earlybird. He has over 16 years of entrepreneurial track record and started investing into early stage digital startups in 2011 after the trade sale of his company DailyDeal to Google Inc. Today, Fabian is focused on SaaS, Marketplaces and Logistics-/Supply Chain Technology. He graduated with honours from Bucerius Law School Hamburg and Heidelberg University and was a visiting Ph.D.-student in Stanford.
Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird focuses on investments in the early stage phase of a company's development, and is among the most experienced in Europe. Earlybird offers portfolio companies not only financial resources, but also strategic and operational support, as well as access to an international network and the capital markets. With over €750 million under management, six portfolio company IPOs as well as 16 trade sales, Earlybird is of one of the most successful venture capital firms in Europe.
For further information, please visit www.earlybird.com
Clemens von Bergmann is a Managing Partner with ALSTIN CAPITAL. He has long-standing expertise as a venture capital investor as well as operational experience at senior executive level. From 2014 to 2016, he served as Managing Director in the insurance business of CHECK24, Germany's largest online comparison portal. From 2005 to 2014 he was an Investment Director and Authorized Officer with High-Tech Gründerfonds where he helped to build the fund to become Germany's (and in 2014 even Europe’s) largest and most active venture capital fund for tech start-ups. He started his career in a facial-recognition start-up. He holds a M.Sc. in Information & Communication Technology and a law degree.
ALSTIN II is a 2nd generation VC Funds focusing on tech companies in the DACH region that have demonstrated a commercial proof-of-concept. The fund bundles the entrepreneurial experience of Carsten Maschmeyer, one of Germanys most successful entrepreneurs with the team’s deep VC investment know-how. ALSTIN actively adds value to its portfolio companies by providing world-class support building the sales organization and sales strategy with its portfolio companies. The fund boasts a highly attractive pipeline of active portfolio companies from the start. Management will invest at least 10% of the fund volume as the team commitment demonstrating an outstanding strong alignment with the fund investors interests.
For further information, please visit www.alstin.de/en/home-en/
Thies Sander is a founding partner at Project A Ventures. In his role, Thies is a trusted advisor to Project A portfolio companies and oversees Project A's investor relations and talent management activities. Before, he was CEO of a German online comparison startup, Principal at The Boston Consulting Group (Berlin, New York) and headed the global operations strategy team at Adidas. He studied in Germany (WHU), USA (Kellogg) and France (ESC Rouen) and holds a degree in business administration.
Project A is a Berlin-based VC founded in 2011 with now €260 million assets under management. Project A’s invests in European early-stage companies in the digital technology space. Besides money the VC provides a unique organisational structure featuring 90 experts, offering portfolio companies hands-on support in the areas of IT, performance & brand marketing, business intelligence, sales and recruiting. Its portfolio includes companies like Kry, Catawiki, WorldRemit, Comtravo and Contorion (exit).
Ingo Potthof (Managing Partner) has more 17 years leadership experience in venture capital in Europe, Israel, the USA and Asia. Before co-founding UVC Partners in 2011, he worked as Partner at smac partners, a specialized secondary investment firm. Prior to this, he was as Partner instrumental in establishing the global seed-stage investment business for Siemens. Ingo has carried out successful investments with a number of trade sales and IPOs. His earlier positions include Telefónica O2, where he worked as Manager M&A and Strategy, and Roland Berger Strategy Consultants.
Unternehmertum Venture Capital Partners (UVC Partners) is an early-stage venture capital firm that invests in technology-based startups in Germany, Austria and Switzerland. UVC Partners focuses on B2B business models in the areas of Industry 4.0, IoT, Manufacturing Technologies, B2B SaaS, Mobility and Smart City. Portfolio companies benefit from the extensive investment and exit experience of the management team as well as from the close cooperation with UnternehmerTUM, Europe's leading innovation and business creation center. With 150 employees and more than 50 industry partners, UnternehmerTUM can draw from many years of experience in establishing young companies. This enables UVC Partners to offer startups unique access to talent, industry customers, and other financial partners. Notable investments include FlixBus, CarJump (acquired by PSA Group), KONUX, Vimcar and VEACT.
For further information please visit www.uvcpartners.com
Nicholas Money-Kyrle (52): Nick founded Steadfast Capital in 2001. He began his career in the German private equity business in 1994 and prior to Steadfast Capital has held investment and management responsibilities with 3i Deutschland, GE Capital and BHF Bank. Prior to private equity, Nick worked for eight years for KPMG in Edinburgh and Düsseldorf. He possesses extensive deal experience primarily in direct LBO participations and also in fund-of-fund and secondary business. Nick is a member of the Institute of Chartered Accountants in Scotland and holds degrees in Finance and Accounting from Leeds Metropolitan University and the Bremen Business College.
Steadfast Capital is an independent private equity business focusing on medium-size businesses within German speaking Europe and Benelux countries. The team has been active in the German private equity market since the 90s making it one of the most established and proven teams in Germany. Over the past 17 years, Steadfast Capital has successfully advised three fund generations and is currently raising Fund IV with a target volume of €250 million.
For further information, please visit www.steadfastcapital.de/en/
Before Matthias started his investment career he spent over 10 years in the German lower midmarket as CEO of the stock listed PEACHES GROUP. Previously he signed responsible for the international restructuring of a leading Austrian technology company. In the years 2010-2014 he headed the business of the Munich and Zug (CH) based early stage investor Mountain Lake Investment. Thereafter he founded BRIGHT CAPITAL and serves since then as a Managing Partner.
BRIGHT CAPITAL is the manager of a credit fund that follows an entrepreneurial investment approach. The fund invests in sustainable German SME´s facing substantial growth opportunities. The BRIGHT CAPITAL team has a successful track record as entrepreneurs and investors. As such, the team sees itself as advising partner towards its portfolio companies, without interfering in the operational business. The management team enjoys strong support from an experienced industrial advisory board.
Please visit www.brightcapital.de for more information.
Christoph D. Kauter is Founder and Managing Partner of Beyond Capital Partners. Over more than one-and-a-half decades, Christoph accumulated in-depth knowledge in the fields of Private Equity, M&A, Corporate Finance and Equity Capital Markets and holds Executive Board responsibility at Private Equity firms since 2008. Christoph has ample transaction expertise, know-how in business development and an extensive industry and investor network which he gained through career stations both in Investment Banking and Private Equity in Germany and the UK.
Beyond´s proven strategy is the acquisition of majority stakes in profitable companies based in the DACH region such as industrial producers, suppliers, consumer goods, service providers and IT firms with annual revenues between €10 million and €100 million. Buy-and-build is an essential element of our portfolio growth strategy. Equity tickets of up to €15 million per investment are our sweet-spot. The portfolio of Fund I comprises currently three companies. We intent to start fund raising for Fund II over the course of 2018.
For further information, please visit www.beyondcapital-partners.com
Dr. Nicolaus Loos is the Head of IKB Deutsche Industriebank’s (“IKB”) Markets Management Committee responsible for all banking and market activities. He joined IKB – a German-headquartered European lending bank – in 2009 to build the Sponsor Leveraged and Corporate Structured Finance business across Europe, with a particular focus on Germany. With over 15 years banking experience, Dr. Loos previously worked in the sponsor-driven business (LBOs, IPOs, M&A) at J.P. Morgan and Morgan Stanley in London, New York and Frankfurt. He holds a Master degree from HHL Leipzig, a M.B.A. from the Australian Graduate School of Management in Sydney and a Doctoral degree from the University of St. Gallen.
IKB Deutsche Industriebank AG supports medium-sized enterprises and private equity funds in Germany and Europe with loans, risk management, capital market services and advisory services. IKB has had close ties with German companies and entrepreneurs since it was founded in 1924. The Bank’s business model is based on stable, long-term customer relationships and a pronounced understanding of issues affecting medium-sized enterprises. IKB’s private debt platform Valin Funds gives European insurance companies and pension funds the opportunity to invest in mid-market Corporates while using IKB’s extensive network. The fund gives mid-market Corporates the opportunity to secure long-term financing up to ten years. IKB will be responsible for the investment for its entire term.
For further information, please visit www.valinfunds.de/